Erenumab
CGRPR | |
Clinical data | |
---|---|
Trade names | Aimovig |
Other names | AMG-334, erenumab-aooe |
AHFS/Drugs.com | Monograph |
MedlinePlus | a618029 |
License data | |
Pregnancy category |
|
Subcutaneous injection | |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 82% (estimated) |
Metabolism | Proteolysis |
Elimination half-life | 28 days |
Identifiers | |
CAS Number | |
DrugBank | |
ChemSpider |
|
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C6472H9964N1728O2018S50 |
Molar mass | 145871.98 g·mol−1 |
Erenumab, sold under the brand name Aimovig, is a
Erenumab, which was developed by Amgen and Novartis,[5] was approved in May 2018, and was the first CGRPR antagonist to be approved by the U.S. Food and Drug Administration.[6] In 2020, it was the 234th most commonly prescribed medication in the United States, with more than 1 million prescriptions.[7][8]
Medical uses
Erenumab is indicated for the prevention of migraine in adults.[3][4]
Side effects
Common side effects are
Interactions
Erenumab was shown not to interact with
Pharmacology
Mechanism of action
Erenumab is a fully human
Pharmacokinetics
After
History
Erenumab was developed by Amgen Inc. in conjunction with Novartis.[5]
In the
Society and culture
Economics
As of 2018, the list price was reported to be US$6,900 per year.[13]
In the United Kingdom, Erenumab was approved by the
Legal status
The United States Food and Drug Administration approved the medication for the preventive treatment of migraine in adults in May 2018. It was the first CGRPR antagonist to be approved.[6] It was approved for medical use in the European Union on July 26, 2018.[4][16]
Names
Erenumab is the international nonproprietary name and the United States Adopted Name.[17][18]
References
- ^ "Erenumab (Aimovig) Use During Pregnancy". Drugs.com. 17 April 2019. Archived from the original on 29 November 2020. Retrieved 5 May 2020.
- ^ "Summary Basis of Decision (SBD) for Aimovig". Health Canada. Archived from the original on 31 May 2022. Retrieved 29 May 2022.
- ^ a b c d e "Aimovig- erenumab-aooe injection Aimovig- erenumab-aooe injection, solution". DailyMed. 19 August 2022. Archived from the original on 5 July 2022. Retrieved 29 September 2022.
- ^ a b c d e f "Aimovig EPAR". European Medicines Agency (EMA). Archived from the original on 17 October 2020. Retrieved 4 May 2020.
- ^ PMID 29171821.
- ^ a b "FDA Approves First-in-Class Drug Erenumab (Aimovig) for Migraine Prevention". Medscape. 17 May 2018. Archived from the original on 25 September 2019. Retrieved 21 May 2018.
- ^ "The Top 300 of 2020". ClinCalc. Retrieved 7 October 2022.
- ^ "Erenumab - Drug Usage Statistics". ClinCalc. Retrieved 7 October 2022.
- ^ a b c "Aimovig: EPAR - Product Information" (PDF). European Medicines Agency. 8 August 2018. Archived (PDF) from the original on 6 October 2018. Retrieved 2 May 2019.
- ^ "Amgen Presents First-Of-Its-Kind Data At AAN Annual Meeting Reinforcing Robust And Consistent Efficacy Of Aimovig (erenumab) For Migraine Patients With Multiple Treatment Failures" (Press release). Amgen. 17 April 2018. Archived from the original on 11 November 2020. Retrieved 29 September 2022 – via PR Newswire.
- PMID 30550780.
- ^ Erenumab to prevent migraine: results from phase III STRIBE" Archived 13 August 2018 at the Wayback Machine, Pharma World, December 14, 2017.
- ^ Kolata G (17 May 2018). "F.D.A. Approves First Drug Designed to Prevent Migraines". The New York Times. Archived from the original on 11 May 2020. Retrieved 26 September 2019.
- ^ Gallagher J (26 September 2019). "'Life-changing' migraine drug rejected for NHS". BBC News Online. Archived from the original on 31 July 2021. Retrieved 26 September 2019.
- ^ "New migraine drug not cost-effective NICE says in draft guidance". NICE. Archived from the original on 1 November 2020. Retrieved 26 September 2019.
- ^ "First drug to prevent chronic migraines approved by EU". The Guardian. 31 July 2018. Archived from the original on 19 September 2018. Retrieved 19 September 2018.
- ^ "Statement On A Nonproprietary Name Adopted By The USAN Council - Erenumab" (PDF). American Medical Association. 24 November 2015. Archived (PDF) from the original on 4 November 2018. Retrieved 4 November 2018.
- ^ World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115" (PDF). WHO Drug Information. 30 (2). Archived (PDF) from the original on 5 February 2018. Retrieved 30 September 2022.